Mammoth Bio hires CBO and GC, adapting "big pharma" playbook

US biotech Mammoth Biosciences, which is building the next generation of CRISPR products to cure and detect disease, has reinforced its C-suite with the arrival of two industry veterans - Phil Tinmouth as chief business officer, and Siang Chin as general counsel.

The pair’s strategic executive leadership should propel Mammoth’s efforts to reshape therapeutics and diagnostics with its expansive pipeline of CRISPR-based products, including “ultra-compact” CRISPR system to support the development of one-time, in vivo cures.

Mr Tinmouth’s experience includes a 20+ year career at Vertex Pharmaceuticals, earning his role as vice president/head of business development and helping grow what was an $800 million company at the beginning of his tenure into the $50 billion pharma giant it is today. He joins Mammoth from Pardes Biosciences, where he led business development and strategic initiatives as Chief Business and Strategy Officer.